Aaron Richard Hansen

44PUBLICATIONS
323CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Primary health care
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Apr 09, 2026
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Jose Luis Perez-Gracia, Begoña Mellado, Aaron Richard Hansen

|Jan 23, 2026
International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR.

Emily Alger, Olalekan Lee Aiyegbusi, Amylou C Dueck

|Dec 22, 2025
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Danny Rischin, Aaron R Hansen, Ezra E W Cohen

|Dec 19, 2025
Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma.

Enrique Sanz-Garcia, Shirin Soleimani, Jeff P Bruce

|Jun 24, 2025
First Nations Australians and head and neck cancer: health professionals' priorities for improving the pathway of care.

Stephanie Ng, Elizabeth C Ward, Gail Garvey

Pageof 8